BrainsWay (TASE:BWAY) Stock Can Profit Growth Justify Its Premium Price

BrainsWay shares came into this earnings print under pressure, down roughly 18% over the past three months, even as expectations around growth and valuation stayed elevated. The stock now trades at a P/E of about 53.8x, with a discounted cash flow estimate of ₪4.23 sitting far below the recent ₪38.89 close. This combination sets a high bar for any report.

The headline this quarter is margin and profit strength. Q2 revenue reached $17.1m, while net income climbed to $2.71m, and trailing net margin reached 15.6%. The market now has to decide whether today’s pullback is simple profit taking or a rethink of that premium multiple.

Is BrainsWay’s 53.8x P/E simply paying up for a strong 15.6% trailing net margin, or has the share price moved too far ahead of the DCF math? Compare the current market price with our valuation analysis for BrainsWay

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$17.107 million vs. US$12.632 million (up about 35%).
• Net Income (Q2 2026 vs. Q2 2025): US$2.71 million vs. US$2.027 million (up about 33.7%).
• Basic EPS (Q2 2026 vs. Q2 2025): US$0.07 vs. US$0.05 (up about 40%).
• Trailing Net Margin (TTM, Q2 2026 vs. Q2 2025): 15.6% vs. 11.6% (margin improved over the past year).

Prefer clean charts instead of another wall of numbers? See BrainsWay’s full financial picture, including a detailed valuation breakdown, in the company report for BrainsWay.

BrainsWay results lean into the bullish story

BrainsWay looks more like a functioning mental health platform than a single product bet. Revenue growth of 35% with system placements up 42% and remaining performance obligations rising to US$80.4m all point toward broader adoption and longer visibility. Profitability is not just theoretical either. Operating income reached US$2.4m and adjusted EBITDA margin moved to 20%, with a debt free balance sheet and US$62.4m in cash. For a med tech focused on interventional psychiatry, that combination of growth, recurring leasing and cash generation fits a constructive long term thesis.

BrainsWay risks still matter, but look contained

Bears worry about execution and adoption risk in a crowded neuromodulation field, and reimbursement still sits at the center of that concern. Management highlights reimbursement variability and the dependence of SWIFT protocol uptake on payer coverage, which directly validates that worry. Minority investments in provider platforms and Neurolief introduce another layer of execution risk, since returns rely on partners scaling effectively. Even so, 12 straight profitable quarters on an adjusted EBITDA basis and stable ~75% gross margin suggest the immediate financial strain that often dogs small med tech plays is not the main issue right now.

With reimbursement still patchy, minority stakes in partners and a volatile share price, investors should review whether these visible concerns mask broader structural weaknesses. Scan the independent risk analysis for BrainsWay which shows 1 important warning sign

Stay Ahead With Simply Wall St

If BrainsWay’s rich P/E and gap to the DCF value have you watching for a better entry point, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value in real time. Once you decide to take a position, use the Portfolio Command Center to cut through day to day noise and focus on the key updates that matter for your holdings. For a longer horizon, tap into crowd insights with the Community and see how other investors are thinking about risks and opportunities. Spot potential catalysts and red flags earlier so you can stay ahead of the market instead of reacting to it late.

Seeking Alternatives Beyond BrainsWay Today

Fresh ideas tend to move first when breakout momentum develops and slow research gets caught flat footed. Scan curated stock shortlists while it matters and act promptly.

• Capture income from companies that aim to keep payouts flowing even when markets wobble by scanning our curated 158 dividend fortresses before yields start dropping.
• Look for potential long-term compounders with strong balance sheets and resilient cash flows using a tightly filtered 192 high quality undervalued stocks while valuations still look reasonable.
• Focus on companies that seek steadier performance and fewer negative surprises through a hand picked 223 resilient stocks with low risk scores before the crowd pursues safety trades.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com